Filter
1692
Text search:
Food
and
Drug
Administration
Featured
198
501
Language
Document type
932
322
221
104
51
25
21
8
3
2
2
1
Countries
107
66
57
49
49
48
39
38
38
36
34
33
30
30
29
25
24
22
21
17
15
14
14
12
11
10
9
9
9
8
8
7
7
7
7
7
6
6
6
5
5
5
5
5
5
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
757
181
78
70
57
24
22
Toolboxes
131
124
122
102
87
69
49
41
35
29
29
27
23
21
16
14
14
12
12
12
9
7
5
4
3
PQM conducted an assessment of the medicine quality assurance and quality control systems in Rwanda during November 9-13, 2009. Medicine quality assurance remains to be developed in Rwanda: the country has neither a medicine regulatory authority (MR
...
A survey of prevention, testing and treatment policies and practices
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Introduction
Chapter A.7
Anxiety disorders
Chapter F.1
2018 edition
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and
...
MMWR Morb Mortal Wkly Rep. ePub: 4 December 2020. DOI: http://dx.doi.org/10.15585/mmwr.mm6949e2
This article was published on December 10, 2020, and updated on December 16, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2034577
3 March 2022
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf
...
This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and
...
International Journal of Basic & Clinical Pharmacology 5(6):2290-2294
DOI: 10.18203/2319-2003.ijbcp20164081
This Mpox SPRP Global Monitoring & Evaluation (M&E) Framework, also referred to as the Framework, aims to monitor and report on global progress towards these objectives, including information about country-level response efforts
...
Since 2000, concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World
...
Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV
recommended
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and
Adolescents With HIV document is published in an electronic format
...
LEAVING NO-ONE BEHIND | “A Journey to End NTDs – Elimination and Care” records what we have achieved over the last year and where we are now. It presents our plan of action for the coming year
...
Antibiotic resistant bacteria are spreading at an alarming rate and some bacterial infections may once again be untreatable. Antibiotic resistance (ABR), conservatively calculated, causes more than 500 000 deaths every year. This number is projected
...
The Panel recommendations on initial combination regimens for the antiretroviral therapy (ART)-naive, HIV-infected patients.
